we evaluated the specific cytotoxicity of anti-CD19 (HD37-dgRTA) and anti-CD22 (RFB4-dgRTA) ITs or their combination (Combotox) on patient-derived pre-B ALL cells maintained in vitro on a stromal ...

Adverse events (AEs) were detected beginning with the CD19/CD22 CAR T cells infusion. AEs were graded according to the NCI Common ... two with transformed follicular lymphoma(TFL) and one with high ...

is a pharmaceutical company and a tumor immunotherapy technology developer. The company is headquartered China. For a complete picture of CD19/CD22 CAR-T’s drug-specific PTSR and LoA scores, buy the ...

Preclinical studies using transgenic mice expressing human CD19 have shown that pre-B cells and their malignant counterparts, as well as pre-existing antibody-producing and autoantibody-producing ...

Among the 194 patients with relapsed or refractory B-ALL treated with the co-administration of CD19- and CD22-CAR-T cells, the median age was 7.6 years (range 0.8–19.6 years). In total, 75 patients ...

Firi-cel is an autologous cell therapy designed to target the cancer protein CD22 ... refractory large B-cell lymphoma (LBCL) that had progressed following treatment with a CD19-targeting CAR ...

The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo. Methods Sequential ultrasound-guided ...

In a devastating blow to the company and large B-cell lymphoma patients relapsed or refractory to CD19 CAR T-cell therapy, Cargo Therapeutics Inc. terminated the phase II study of its lead CD22 cell ...

Cargo Therapeutics discontinued a study evaluating firicabtagene autoleucel, an autologous CD22 chimeric antigen receptor (CAR) T-cell therapy for large B-cell lymphoma and the company’s lead ...